{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:24Z","timestamp":1791932604348,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effectiveness, safety, and convenience of in\u2010class transition (iCT) from intravenous bortezomib\u2010based induction to ixazomib\u2010based oral regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective real\u2010world study was conducted in 16 Chinese hospitals between October 2017 and April 2023 and analyzed newly diagnosed (NDMM) and first\u2010line relapsed multiple myeloma (FRMM) patients who attained at least a partial response from bortezomib\u2010based induction therapy, followed by an ixazomib\u2010based oral regimen for 2\u2009year or until disease progression or intolerable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study enrolled 199 patients, median age: 63\u2009years old, male 55.4%, 53% as high risk (HR), and 47% as standard risk. Cytogenetic risk stratification by metaphase fluorescence in\u00a0situ hybridization (M\u2010FISH), based on the Mayo Clinic risk stratification system. The median duration of total PI therapy was 11\u2009months, with ixazomib\u2010based treatment spanning 6\u2009months. At the 20\u2010month median follow\u2010up, 53% of patients remained on therapy. The 24\u2010month PFS rate was 84.3% from the initiation of bortezomib\u2010based induction and 83.4% from the start of ixazomib\u2010based treatment.<\/jats:p><jats:p>Overall response rate (ORR) was 100% post\u2010bortezomib induction and 90% following 6\u2009cycles of the ixazomib\u2010based regimen. Based on the Sankey diagrams, 89.51% of patients maintained or improved their disease response after 2\u2009cycles of iCT, 6\u2009cycles (90.14%), and 12\u2009cycles (80%). The HR level of Mayo was found to be a significant independent factor in a worse remission (hazard ratio (HR) 2.55; <jats:italic>p<\/jats:italic>\u2009=\u20090.033).<\/jats:p><jats:p>Ixazomib's safety profile aligned with previous clinical trial data, with 49% of patients experiencing at least one AE of any grade. The most common AEs included peripheral neuropathy, nausea and vomiting, diarrhea, thrombocytopenia, and granulocytopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the real\u2010world Chinese MM population, NDMM and FRMM patients responded favorably to PI\u2010based continuous therapy, demonstrating substantial response rates. The ixazomib\u2010based iCT allows for sustained PI\u2010based treatment, offering promising efficacy and tolerable AEs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.7177","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:18:15Z","timestamp":1714468695000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of prolonged proteasome inhibition through <scp>ixazomib\u2010based<\/scp> oral regimen on newly diagnosed and first\u2010relapsed multiple myeloma: A <scp>real\u2010world<\/scp> Chinese cohort study"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-4298","authenticated-orcid":false,"given":"Aijun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology Beijing Chaoyang Hospital, Affiliated to Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin Medical University General hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hou","sequence":"additional","affiliation":[{"name":"School of Public Health Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology Henan Provincial people's hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2010ling","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking Union Medical Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Jishuitan Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology China\u2010Japan Friendship Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The Fourth hospital, Affiliated to Hebei Medical University  Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoming","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Hebei University  Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology Second hospital of Shanxi Medical University  Taiyuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Hospital of Inner Mongolia Medical University  Hohhot China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology Inner Mongolia Autonomous Region People's Hospital  Hohhot China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Suo","sequence":"additional","affiliation":[{"name":"Department of Hematology Han Dan Central Hospital  Handan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology Sheng Jing Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology China\u2010Japan Union Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology Tianjin Medical University General hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-5045","authenticated-orcid":false,"given":"Deqiang","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Public Health Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-8489","authenticated-orcid":false,"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Chaoyang Hospital, Affiliated to Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2901-x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1195254"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.024"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113441"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126606"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03985-9"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.436"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112046"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128865"},{"key":"e_1_2_10_15_1","first-page":"1865","article-title":"Real world data on the efficacy and safety of Ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: data collected from the Hungarian Ixazomib named patient program","volume":"130","author":"Varga G","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136519"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04234-9"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07732-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0272"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00912-9"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0018-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791228"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13435"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000432"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25113"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022806"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2208439"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03479-6"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03981-z"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1225"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.7177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:58:00Z","timestamp":1728572280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.7177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/cam4.7177"],"URL":"https:\/\/doi.org\/10.1002\/cam4.7177","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e7177"}}